在人类肝细胞中对pexidartinib诱导的毒性进行机制性研究
Chemico-biological interactions
|July 5, 2025
概括
佩克西达丁尼 (pexidartinib) 通过亡,ER压力和线粒体功能障碍导致肝细胞死亡. 细胞染色体P450的新陈代谢可以防止pexidartinib的毒性.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学 是一个学科.
- 分子毒理学 分子毒理学
背景情况:
- 佩克西达丁尼 (pexidartinib) 是一种氨酸激酶抑制剂,已获得FDA批准,用于治疗紧突巨细胞瘤.
- 佩克西达丁尼布带有肝毒性警告框,但其机制尚未完全理解.
- 有限的机制研究存在于pexidartinib诱导的肝损伤.
研究的目的:
- 调查皮克西达丁尼布诱导的肝毒性背后的机制.
- 探索细胞染色体P450 (CYP) 酶在pexidartinib毒性中的作用.
主要方法:
- 在初级人类肝细胞和HepG2细胞中评估了pexidartinib的细胞毒性.
- 评估的亡,内质网膜 (ER) 压力和线粒体功能障碍.
- 利用CYP工程的HepG2细胞系和CYP抑制剂来研究新陈代谢.
主要成果:
- 佩克西达丁尼 (pexidartinib) 降低了肝细胞的细胞活力,诱导了细胞亡,ER压力和线粒体功能障碍.
- 抑制CYP1A1,2C9和3A4/5加剧了pexidartinib诱导的细胞毒性.
- 鉴定出CYP1A1,2C9,3A4和3A5是pexidartinib的主要代谢剂.
结论:
- 佩克西达丁尼布通过亡,ER压力和线粒体功能障碍诱导肝毒性.
- 通过CYP介导的新陈代谢通过降低pexidartinib的毒性来发挥保护作用.
- 了解这些机制可能会为减轻与pexidartinib相关的肝损伤的策略提供信息.
相关概念视频
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
01:21Toxicokinetics: Overview
314
Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...
314